#ICYMI: An important $CYCN shareholder vote is underway! Our Board has unanimously approved a proposed merger with Korsana Biosciences and recommends a vote “FOR” the proposals. This transaction represents a transformative opportunity & cannot proceed without your vote.

Calling all $CYCN shareholders! Our Board has unanimously approved a proposed merger with Korsana Biosciences and recommends a vote “FOR” the 11 important proposals described in the proxy materials which have been mailed to you. Vote today!

Our Board has approved a proposed merger with Korsana Biosciences, representing a transformative opportunity for $CYCN shareholders. To learn more, please review the proxy materials that were mailed to you.

We’re pleased to announce a merger agreement with Korsana Biosciences! This transaction is the result of a comprehensive strategic review, and we believe it represents the best path forward for Cyclerion. Read more: ir.cyclerion.com/news-releas…

We’re pleased to share the latest progress toward initiating our Phase 2 proof-of-concept study of CYC-126 for treatment-resistant depression with positive pre-IND FDA feedback and the formation of our Clinical Advisory Board. ir.cyclerion.com/news-releas…

Congratulations, @akebiatx, on dosing the first patient in their Phase 2 trial of legacy Cyclerion asset praliciguat in focal segmental glomerulosclerosis (FSGS), a rare kidney disease.

We’re kicking off 2026 with the exciting news of our exclusive collaboration with @medsteer. We’re advancing CYC-126, a first-of-its-kind, precision therapy for treatment-resistant depression, and expect to initiate a Ph2 POC trial this year. ir.cyclerion.com/news-releas…

We're excited to be at the Guggenheim Healthcare Innovation Conference, sharing more about our focus on advancing the first personalized therapeutic approach for people living with treatment-resistant depression!

Congratulations to our Board member, Dina Katabi, on being elected to @theNAMedicine! Her accomplishments include pioneering digital health monitoring technology that uses AI & wireless signals, and developing digital biomarkers for Parkinson’s. nam.edu/news-and-insights/10…

Investor webcast today at 10:30am ET about our new focus on neuropsychiatric conditions, starting w/ treatment-resistant depression. Based on IP licensed from @MIT_TLO, our lead candidate combines common anesthetics with a proprietary tech-driven system. ir.cyclerion.com/news-events…

Cyclerion has entered into a licensing agreement with @MIT_TLO, securing the IP enabling our transformation into an innovation-driven company focused on delivering therapies for neuropsychiatric conditions, starting with treatment-resistant depression. cyclerion.gcs-web.com/news-r…

We’re pleased to share how we are leveraging our legacy sGC stimulator assets to generate near-term revenues to catalyze our next stage of growth. Learn about our praliciguat license agreement amendment & olinciguat license option agreement here: ir.cyclerion.com/news-releas…

We’re excited to announce Regina Graul, a drug hunter with 20+ yrs of experience, is the new president of Cyclerion! Peter Hecht is stepping down as CEO but remains on our Board and looks forward to working closely with Regina to advance our mission. ir.cyclerion.com/news-releas…

Symptoms of #mitodisease, including #MELAS, vary considerably - even patients with the same genetic change can have very different symptoms. #WorldMitoWeek

Its #WorldAlzheimersDay! For the 28th time, people unite from all corners of the world to raise awareness and to challenge the stigma that persists around Alzheimer’s disease and all types of dementia.

#Mitochondria process oxygen and convert the foods we eat into energy—so when things go wrong, it can mean robbing the body’s cells of energy, often causing organ dysfunction. #WorldMitoWeek

It’s #WorldMitoWeek! Every year, people and places all around the world #LightUpForMito to show their support for patients and families impacted by #mitochondrialdisease.

Add your flower to the fight! On Oct 16th, join Cyclerion as we raise awareness and funds for Alzheimer’s care, support, and research at @alzassociation’s #Walk2EndALZ. View or support our progress towards our goal here: bit.ly/3d4zV1P

This #WorldAlzMonth, it’s important to distill misconceptions and #KnowDementia #KnowAlzheimers. By continuing to raise global awareness and knowledge, we are better armed with information and advice to prepare, adapt, and support those who are most affected.

We’re honored to sponsor this year’s @UMDF #EnergyforLife Walkathon! #WalkYourWay on Oct 1 and support UMDF’s mission to promote research & education for the diagnosis, treatment and cure of #mito disorders. View or support our progress towards our goal: ow.ly/VvoH50KIhtb